Targets › TCR
1 program from 1 company in 3 trials: 3 Phase 2; Oncology; next expected readout Oct 2027.
Open in Phaseline: the race on TCR, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| National Cancer Institute (NCI) | Young TIL T cell receptor (TCR)-engineered tumor infiltrating lymphocytes (TIL) therapy | TCR | Phase 2 | Advanced Non-Small Cell Lung Cancer; Melanoma; Metastatic Colorectal Cancer | Oct 2027 |
Advanced Non-Small Cell Lung Cancer (1) Melanoma (1) Metastatic Colorectal Cancer (1)
mixed (1)
National Cancer Institute (NCI) (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.